<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081636</url>
  </required_header>
  <id_info>
    <org_study_id>5479</org_study_id>
    <nct_id>NCT04081636</nct_id>
  </id_info>
  <brief_title>Prostate Biopsy: Efficacy and Complications</brief_title>
  <acronym>ProBE-PC</acronym>
  <official_title>Prospective, Randomized Study of Prostate Biopsy: Reducing Complications and Improving Efficacy (ProBE-PC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the difference between 2 prostate biopsy methods, transrectal (through
      the rectal wall) and transperineal (through the skin) needle biopsy.

      Men who are in need of prostate biopsy due to clinical suspicions of prostate cancer will be
      randomly assigned (1:1) to either transrectal or transperineal approach.

      This research study will scientifically determine if one biopsy method is better than the
      other in reducing complications and improving cancer detection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two ways to take biopsy (tissue) samples from the prostate. The more commonly used
      method is trans-rectal needle biopsy of the prostate (TR-Bx) with a needle inserted through a
      probe in the rectum to reach the prostate.

      TR-Bx is usually performed in the office, using local anesthesia, and often using a targeted
      biopsy approach using MRI/ultrasound fusion technique.

      Trans-perineal biopsy (TP-Bx) with a needle inserted directly through the skin to reach the
      prostate.

      Typically, TP-BX is performed in the outpatient surgical setting due significant pain
      associated with the procedure, requiring the use anesthesia and/or sedation.

      TP-Bx. procedure is very uncommon in the USA and is often performed using ultrasound alone
      (less accurate), without the benefit of MRI guided targeted biopsy.

      Now, with the availability of new devices, we are able to perform both TR-Bx and TP-Bx using
      MRI/ultrasound fusion guided targeted approach, in the office setting, using local anesthesia
      alone.

      With the TR-Bx, there has been increasing risk of infection related complications, sepsis and
      hospital admissions.

      The newer approach of biopsy TP-Bx may cause fewer infections and may have a higher accuracy
      of finding cancer.

      This randomized study of TR-BX and TP-Bx will address these questions:

        -  Differences in the risk of infectious complications

        -  Differences in the hemorrhagic and urinary side effects

        -  Tolerability of both techniques with local anesthesia alone

        -  Difference in the results of of MRI/US fusion targeted biopsy

        -  Differences in the overall cancer detection rate and the high-grade cancer detection
           rate

        -  Differences in the cost of the procedures
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1 to either trans-rectal needle biopsy (TR-Bx) or Trans-perineal biopsy (TP-Bx) of the prostate.
Both arms, either with or without MRI guided biopsy</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of infectious complications</measure>
    <time_frame>30 days</time_frame>
    <description>Whether or not patient had an infection after the biopsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Bleeding complications</measure>
    <time_frame>30 days</time_frame>
    <description>The type of bleeding and its severity (blood in urine or stool)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer detection rate</measure>
    <time_frame>30 days</time_frame>
    <description>The number of cancers and type (grade) of cancers detected in each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability under local anesthesia</measure>
    <time_frame>30 days</time_frame>
    <description>Pain scores; Need for additional analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported urinary function measures using IPSS questionaire</measure>
    <time_frame>30 days</time_frame>
    <description>International Prostate Symptoms Score (IPSS) to measure urinary function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of the procedures</measure>
    <time_frame>30 days</time_frame>
    <description>Differences in the actual cost of the procedures (including supplies, time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported sexual function measures using IIEF questionaire</measure>
    <time_frame>30 days</time_frame>
    <description>International Index of Erectile Function (IIEF) to measure sexual dysfunction</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">568</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>PSA</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Systematic Transrectal biopsy (TR-Bx)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ultrasound guided; needle inserted through the rectum to reach the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted Transrectal biopsy (TR-Bx)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MRI-guided; needle inserted through the rectum to reach the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systematic Transperineal biopsy (TP-Bx)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound guided; needle inserted directly through the skin to reach the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted Transperineal biopsy (TP-Bx)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI-guided; needle inserted directly through the skin to reach the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systematic Transrectal biopsy (TR-Bx)</intervention_name>
    <description>Through the rectum</description>
    <arm_group_label>Systematic Transrectal biopsy (TR-Bx)</arm_group_label>
    <other_name>ultrasound guided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted Transrectal biopsy (TR-Bx)</intervention_name>
    <description>Through the rectum</description>
    <arm_group_label>Targeted Transrectal biopsy (TR-Bx)</arm_group_label>
    <other_name>MRI guided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systematic Transperineal biopsy (TP-Bx)</intervention_name>
    <description>Through the perineal skin</description>
    <arm_group_label>Systematic Transperineal biopsy (TP-Bx)</arm_group_label>
    <other_name>ultrasound guided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted Transperineal biopsy (TP-Bx)</intervention_name>
    <description>Through the perineal skin</description>
    <arm_group_label>Targeted Transperineal biopsy (TP-Bx)</arm_group_label>
    <other_name>MRI guided</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who are scheduled to undergo prostate biopsy for suspected prostate
             cancer as part of their regular medical care

          -  Either with or without an MRI

        Exclusion Criteria:

          -  Patients with no access to rectum (due to previous rectal surgery)

          -  Any abnormalities of the perineal skin (e.g. infection)

          -  Patients whose procedure requires sedation or general anesthesia

          -  Patients who are unable to undergo &quot;limited&quot; sampling (2-3 needle samples) due to the
             following reasons:

          -  Patients who are unable to temporarily stop anticoagulation medications

          -  Immunocompromised patients who are at increased risk of infection

          -  Physician preference (e.g. older age; low risk of having cancer)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Badar M Mian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brenda Romeo, CCRC</last_name>
    <phone>518-262-8579</phone>
    <email>amcurologyresearch@amc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Romeo, CCRC</last_name>
    </contact>
    <investigator>
      <last_name>Hugh fisher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashar Ata, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Choi YH, Kang MY, Sung HH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Kim CK, Park BK, Lee HM. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13.</citation>
    <PMID>30415878</PMID>
  </reference>
  <reference>
    <citation>Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.</citation>
    <PMID>29552975</PMID>
  </reference>
  <reference>
    <citation>Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.</citation>
    <PMID>28336078</PMID>
  </reference>
  <reference>
    <citation>Wu YP, Li XD, Ke ZB, Chen SH, Chen PZ, Wei Y, Huang JB, Sun XL, Xue XY, Zheng QS, Xu N. Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy. Infect Drug Resist. 2018 Sep 17;11:1491-1497. doi: 10.2147/IDR.S171162. eCollection 2018.</citation>
    <PMID>30271182</PMID>
  </reference>
  <reference>
    <citation>Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol. 2017 Mar;71(3):353-365. doi: 10.1016/j.eururo.2016.08.004. Epub 2016 Aug 17. Review.</citation>
    <PMID>27543165</PMID>
  </reference>
  <reference>
    <citation>Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. J Urol. 2017 Aug;198(2):329-334. doi: 10.1016/j.juro.2017.01.103. Epub 2017 Mar 29.</citation>
    <PMID>28363690</PMID>
  </reference>
  <reference>
    <citation>Saade EA, Suwantarat N, Zabarsky TF, Wilson B, Donskey CJ. Fluoroquinolone-Resistant Escherichia coli Infections After Transrectal Biopsy of the Prostate in the Veterans Affairs Healthcare System. Pathog Immun. 2016;1(2):243-257.</citation>
    <PMID>27774521</PMID>
  </reference>
  <reference>
    <citation>Xiang J, Yan H, Li J, Wang X, Chen H, Zheng X. Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2019 Feb 13;17(1):31. doi: 10.1186/s12957-019-1573-0.</citation>
    <PMID>30760274</PMID>
  </reference>
  <reference>
    <citation>Skouteris VM, Crawford ED, Mouraviev V, Arangua P, Metsinis MP, Skouteris M, Zacharopoulos G, Stone NN. Transrectal Ultrasound-guided Versus Transperineal Mapping Prostate Biopsy: Complication Comparison. Rev Urol. 2018;20(1):19-25. doi: 10.3909/riu0785.</citation>
    <PMID>29942197</PMID>
  </reference>
  <reference>
    <citation>Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K, Wagenlehner FME. Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology. 2017 Jun;104:11-21. doi: 10.1016/j.urology.2016.12.011. Epub 2016 Dec 19. Review.</citation>
    <PMID>28007492</PMID>
  </reference>
  <reference>
    <citation>Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):524-532. doi: 10.1038/s41391-018-0056-7. Epub 2018 Jul 9.</citation>
    <PMID>29988098</PMID>
  </reference>
  <reference>
    <citation>Stefanova V, Buckley R, Flax S, Spevack L, Hajek D, Tunis A, Lai E, Loblaw A; Collaborators. Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability. J Urol. 2019 Jun;201(6):1121-1126. doi: 10.1097/JU.0000000000000156.</citation>
    <PMID>30835607</PMID>
  </reference>
  <reference>
    <citation>Meyer AR, Joice GA, Schwen ZR, Partin AW, Allaf ME, Gorin MA. Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. Urology. 2018 May;115:8-13. doi: 10.1016/j.urology.2018.01.021. Epub 2018 Feb 1.</citation>
    <PMID>29409845</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Badar Mian</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Prostate biopsy</keyword>
  <keyword>PSA</keyword>
  <keyword>infection</keyword>
  <keyword>bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

